Emerging role of lisocabtagene maraleucel chimeric antigen receptor-T cell in nodal and gastrointestinal follicular lymphoma

Figure 1 Mechanism of action of cluster of differentiation 19-directed chimeric antigen receptor-T cell therapy (lisocabtagene maraleucel). Schematic representation of the mechanism of action of lisocabtagene maraleucel. Peripheral blood mononuclear cells are collected by leukapheresis and transduced ex vivo with a lentiviral vector encoding the cluster of differentiation (CD) 19-directed chimeric antigen receptor (CAR) construct, consisting of an antigen-binding domain, transmembrane, and intracellular signaling domains. Following lymphodepleting chemotherapy with fludarabine and cyclophosphamide, the engineered CAR-T cells are reinfused into the patient. Upon recognition and binding to CD19 on malignant B cells, CAR-T cells are activated, proliferate, release cytokines, and induce tumor cell killing. Long-term immune surveillance is mediated by memory T cells. CD: Cluster of differentiation; CAR: Chimeric antigen receptor.